Prof. James McCarthy
Associate Professor
School of Basic Medical Science
Tsinghua University
biography
James McCarthy is Professor of Medicine at the Peter Doherty Institute, University of Melbourne, Laboratory Head at WEHI and Chief Scientific Officer Doherty Clinical Trials Pty Ltd. Until July of 2026 he was Head of the Department of Infectious Diseases at Royal Melbourne Hospital. He is an NHMRC Investigator Fellow and Fellow of the Australian Academy of Health and Medical Sciences. He was awarded the Ralph Doherty QIMR Berghofer Prize for outstanding achievement and leadership in medical research.
McCarthy has over 15 years of experience leading early phase clinical trials entailing human challenge studies with pathogenic organisms including Plasmodium, influenza, hookworm, Strep. pyogenes and N. gonorrhoeae. In these studies, he has provided end-to-end leadership, including cGMP manufactures, gaining ethical and governance approval, engaging with regulatory agencies (FDA, OGTR & TGA), biotech and pharmaceutical companies as well as philanthropic donors (BMGF, Medicines for Malaria, Wellcome Trust, NIH and WHO). As well as using these trial systems for drug and vaccine development, he has leveraged them to probe the host pathogen relationship in human infectious diseases. This work has led to multiple publications, including in in Immunity, Nature, JCI, Nature Immunology, Lancet and NEJM.
Title
A new platform to undertake experimental medicine
abstract
A significant weakness of clinical studies of human infections is the inability to collect data across the entire interval of the human host-pathogen interaction. This is of, particular importance where prospective comparison of host responses at baseline to those at peak infection and convalescence is necessary to inform understanding differences between the first and subsequent encounters. This is of significant practical relevance given the growing appreciation of the importance of both trained immunity and immune imprinting (aka Original Antigenic Sin) in vaccine efficacy. For example, malaria vaccines are significantly more effective in naïve Europeans than they are in pre-exposed African children. In this presentation, I will describe the use of so-called human challenge studies to improve the understanding of the host-pathogen interaction.
